Ex­clu­sive: UK biotech rais­es $33.1M to test CF drug that could work on top of stan­dard of care

En­ter­prise Ther­a­peu­tics closed a £26 mil­lion Se­ries B round to fund a Phase IIa tri­al of its cys­tic fi­bro­sis drug, which aims to sig­nif­i­cant­ly im­prove hy­dra­tion and clear away the mu­cus that makes breath­ing dif­fi­cult for these pa­tients.

Panakes Part­ners led the round, along with par­tic­i­pa­tion from big-name ex­ist­ing in­vestors like Ver­sant Ven­tures, No­var­tis Ven­ture Fund and For­bion.

The UK-based biotech plans to dose the first pa­tient with ETD001, its lead drug, in a Phase IIa tri­al around East­er, CEO John Ford told End­points News, with the first batch of da­ta set to come out in mid-2025. The tri­al, which will be con­duct­ed in the UK and Eu­rope, has al­ready se­cured reg­u­la­to­ry ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER